Quantcast

Latest Sunitinib Stories

2008-09-23 09:01:09

By Barry Nelson CANCER campaigner Barbara Selby has died without ever getting the advanced drug she believed could prolong her life. The plight of Mrs Selby, who spent more than a year trying to persuade her local NHS primary care trust to fund her treatment with a drug called Sutent, was first highlighted by The Northern Echo. The grandmother and mother-of-three died peacefully at her home in Richmond early last Friday. Mrs Selby, a former NHS nurse from Richmond, who turned 65 last...

2008-09-19 00:00:10

Cancer sufferers in the South West were unhappy with the lack of answers they received at a meeting to discuss the use of life- prolonging drugs yesterday. Patients suffering with the disease attended a meeting with the National Institute of Clinical Excellence (NICE) in Plymouth to find out why drugs that prolong a person's life are not widely available on the NHS. Sutent has been rejected for use on the NHS because it is not seen as being cost effective and NICEs believe it only...

2008-09-16 09:00:53

Roche has announced that the final analysis of the Avastin in lung study in patients with advanced lung cancer has shown that not only did the drug significantly slow down the disease progression, it also enabled some patients to survive for over one year, the longest survival ever reported in patients with this advanced disease. The Phase III Roche-sponsored AVAiL study in patients with previously untreated, advanced non-small cell lung cancer (NSCLC), has confirmed that Avastin...

2008-09-16 03:00:09

EAST HANOVER, N.J., Sept. 16 /PRNewswire-FirstCall/ -- New data continue to demonstrate the potential benefit of RAD001 (everolimus) for patients with advanced kidney cancer who have failed standard therapies. Updated study findings from the RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) study show that patients receiving RAD001 had no tumor growth for nearly 5 months vs. 1.9 months for patients receiving placebo (hazard ratio = 0.33 with 95% CI 0.25 to 0.43; p-value...

2008-09-11 09:00:48

According to a new study by Cutting Edge Information, tyrosine kinase inhibitors may have five oncology drugs with annual sales over $1 billion by 2013. This list of blockbuster oncology drugs includes Novartis' Gleevec. Annual sales of Gleevec are projected to steadily grow to $4.6 billion dollars in 2012, making it a top five oncology drug. There are four other approved tyrosine kinase inhibitors that are estimated to surpass $1 billion in annual sales by 2013, one of which is Pfizer's...

2008-09-11 09:00:48

Argos Therapeutics has initiated a Phase IIa trial of its AGS-003 therapy, in combination with sunitinib, for the treatment of newly diagnosed advanced renal cell carcinoma. Approximately 50 subjects with advanced renal cell carcinoma (RCC) will be enrolled in the Phase IIa trial. The study will be conducted at up to 15 sites in North America. The primary study objective is to evaluate clinical activity of AGS-003 in combination with sunitinib, as defined by RECIST criteria. Secondary...

2008-09-10 18:00:08

By Martin Shipton A DAUGHTER whose father suffers from cancer has today appealed directly to Health Minister Edwina Hart for those in his position to be given the drugs that could prolong their lives. Anna Wolfenden's open letter to Ms Hart calls for a swift decision to be made about the availability of drugs such as Sunitinib that are widely available for patients with kidney cancer in the United States and other countries but have failed to secure the recommendation of NHS bodies in...

2008-09-10 09:00:09

Argos Therapeutics today announced the initiation of a Phase 2a trial of its AGS-003 therapy, in combination with sunitinib, for the treatment of newly diagnosed advanced renal cell carcinoma (RCC). AGS-003 is a product of the Company's Arcelis(TM) technology, which is an immunotherapy platform for creating personalized, RNA-loaded, dendritic cell-based therapies perfectly matched to each patient's unique tumor burden. In vitro and animal model studies of the impact of sunitinib on the...

2008-09-09 00:00:26

Campaigners battling for a cancer victim have been told their case is not exceptional enough. Family and friends of Kay Hopkins, from Harriseahead, are fighting for NHS North Staffordshire to provide the kidney cancer drug Sutent, which has not been approved by the National Institute for Health and Clinical Excellence. They argue that Kay's is an exceptional case. Without the drug it is not safe to operate on her kidney tumour. The 70-year-old wife's supporters had written to NHS...

2008-09-08 18:00:09

Pfizer announced today that important study results involving the company's leading anticancer agent, SUTENT(R) (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12--16 September 2008. Researchers will present results of several analyses evaluating the cost effectiveness of SUTENT(R) as first-line therapy in patients with metastatic renal cell carcinoma...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related